CO.DON AG
CO.DON AG: EU approval of the articular cartilage product by the European Commission
CO.DON AG / Key word(s): Regulatory Approval CO.DON AG (ISIN: DE DE000A1K0227) EU approval of the articular cartilage product by the European Commission Berlin / Teltow, 12 July 2017 – Today, CO.DON AG received the Commission’s implementing decision of 10.07.2017 on the granting of marketing authorization for the human pharmaceutical product “Spherox – Spheroids from human autologous matrix-associated chondrocytes”, pursuant to Regulation (EC ) No 726/2004 of the European Parliament and of the Council. The approved indication is the repair of symptomatic joint cartilage defects of the ICRS grade III or IV of the femoral condylar and the patella of the knee with defects of up to 10 cm² in adults. Further Informationen: Matthias Meißner, M.A. Investor Relations
12-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | CO.DON AG |
Warthestraße 21 | |
14513 Teltow | |
Germany | |
Phone: | 03328 43460 |
Fax: | 03328 434643 |
E-mail: | info@codon.de |
Internet: | www.codon.de |
ISIN: | DE000A1K0227 |
WKN: | A1K022 |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
End of Announcement | DGAP News Service |